Empagliflozin role in the treatment of type 2 diabetes with cardiovascular disease and subclinical cardiovascular disease in outpatient setting: case reports
- Journal of Diabetes, Metabolic Disorders & Control
-
Rajesh Jain,1 Mohammadreza Shoghli,2 Muhammad Iqbal,3 Amit Chauhan,4 Rachna Jain5
Abstract
SGLT2 inhibitors based on recent evidence have shown promising Cardio vascular benefits apart from Glycemic Control in T2DM management. ESC-EASD 2019 clearly suggest that All SGLT2i reduces CV risk (3P MACE), HHF, worsening of Nephropathy .Only Empagliflozin has been recommended for reducing the Risk of CV death in T2DM with ASCVD & the CV death remains independent of baseline HbA1c or control of HbA1c. Empagliflozin CV death is very unique because the consistency of Mortality benefit remains very significant in patients of T2DM with various CVD (like Single Vessel disease CAD, Multiple Vessel Disease CAD, Prior CABG, Prior MI, Prior Stroke, Prior HHF, PAD).
Keywords
type 2 diabetes, cardiovascular disease, subclinical cardiovascular disease, coronary artery disease, left ventricular mass index, peripheral arterial disease
